China drug regulator accepts Novo Nordisk's application for oral Wegovy

Novo Nordisk said China’s drug regulator has accepted its marketing application for the oral version of Wegovy. This regulatory milestone supports potential expansion of demand for its weight-loss franchise, though it is not yet an approval or revenue number. Overall sentiment is modestly positive on deal/launch optionality in a major market.